Cell therapy weekly: autologous cell therapy receives IND approval for rare pediatric bone disease

This week: the US FDA has approved an Investigational New Drug Application for an autologous cell therapy product for the treatment of congenital pseudoarthrosis of the tibia, WuXi AppTec completes their acquisition of OXGENE to strengthen their cell and gene therapy service, and Manchester BIOGEL launches their PeptiGel® Organoid Starter Kit for spheroid and organoid cultures. The news highlights: Autologous cell therapy receives IND approval for rare pediatric bone disease WuXi AppTec completes acquisition of OXGENE to strengthen cell and gene therapy service Manchester BIOGEL launches PeptiGel® Organoid Starter Kit for spheroid and organoid cultures   Autologous cell therapy receives...